Q-omics provides the consensus-scored NAT14 profile across patient tissues and cancer cell-line models. NAT14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NAT14 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, NAT14 RNA expression shows 17,874 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where NAT14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAT14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAT14 survival associations across molecular data types. NAT14 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAT14 RNA expression–survival associations across cancer types. High NAT14 expression shows unfavorable associations in MESO, ACC, KIRC, SKCM, UCS and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NAT14 RNA expression.
This table summarizes NAT14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NAT14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAT14 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, BRCA and CHOL. The HNSC box plot shows higher NAT14 RNA expression in tumor versus normal tissue (log2 FC = +1.647, t-test p < 0.001).
This table shows molecular features associated with NAT14 in patient tissues and cancer cell lines. In patient samples, NAT14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAT14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
